source
- Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goalTaiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & Johnson in a lung canc…
- AI monitoring tool could generate up to 82-fold ROI in phase-3 oncology trials, study findsAn analysis by the Tufts Center for the Study of Drug Development found that an artificial-intelligence clinical monitoring agent can produce an estimated 82-fold return on investment in phase-3 on…